
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Barcelona, Spain - Identifying the cause of itch is the key to treating it. New research is helping better characterize pruritus, leading to more effective therapies for this frustrating condition, according to physicians reporting at the 2003 meeting of the European Academy of Dermatology and Venereology (EADV).






